OBJECTIVES: Fat quality and quantity may affect health similarly or differently. Fat quality can be assessed by measuring fat density on CT scan (greater density = smaller, higher quality adipocytes). We assessed the effects of tesamorelin, a growth hormone-releasing hormone analogue that reduces visceral fat (VAT) quantity in some people living with HIV (PWH), on fat density. DESIGN: Participants from two completed, placebo-controlled, randomized trials of tesamorelin for central adiposity treatment in PWH were included if they had either a clinical response to tesamorelin (VAT decrease ≥8%, ≈70% of participants) or were placebo-treated. METHODS: CT VAT and subcutaneous fat (SAT) density (Hounsfield Units, HU) were measured by a central blinded reader. RESULTS: Participants (193 responders, 148 placebo) were 87% male and 83% white. Baseline characteristics were similar across arms, including VAT (-91 HU both arms, P = 0.80) and SAT density (-94 HU tesamorelin, -95 HU placebo, P = 0.29). Over 26 weeks, mean (SD) VAT and SAT density increased in tesamorelin-treated participants only [VAT: +6.2 (8.7) HU tesamorelin, +0.3 (4.2) HU placebo, P < 0.0001; SAT: +4.0 (8.7) HU tesamorelin, +0.3 (4.8) HU placebo, P < 0.0001]. The tesamorelin effects persisted after controlling for baseline VAT or SAT HU and area, and VAT [+2.3 HU, 95% confidence interval (4.5-7.3), P = 0.001) or SAT (+3.5 HU, 95% confidence interval (2.3-4.7), P < 0.001] area change. CONCLUSION: In PWH with central adiposity who experienced VAT quantity reductions on tesamorelin, VAT and SAT density increased independent of changes in fat quantity, suggesting that tesamorelin also improves VAT and SAT quality in this group.
OBJECTIVES: Fat quality and quantity may affect health similarly or differently. Fat quality can be assessed by measuring fat density on CT scan (greater density = smaller, higher quality adipocytes). We assessed the effects of tesamorelin, a growth hormone-releasing hormone analogue that reduces visceral fat (VAT) quantity in some people living with HIV (PWH), on fat density. DESIGN: Participants from two completed, placebo-controlled, randomized trials of tesamorelin for central adiposity treatment in PWH were included if they had either a clinical response to tesamorelin (VAT decrease ≥8%, ≈70% of participants) or were placebo-treated. METHODS: CT VAT and subcutaneous fat (SAT) density (Hounsfield Units, HU) were measured by a central blinded reader. RESULTS: Participants (193 responders, 148 placebo) were 87% male and 83% white. Baseline characteristics were similar across arms, including VAT (-91 HU both arms, P = 0.80) and SAT density (-94 HU tesamorelin, -95 HU placebo, P = 0.29). Over 26 weeks, mean (SD) VAT and SAT density increased in tesamorelin-treated participants only [VAT: +6.2 (8.7) HU tesamorelin, +0.3 (4.2) HU placebo, P < 0.0001; SAT: +4.0 (8.7) HU tesamorelin, +0.3 (4.8) HU placebo, P < 0.0001]. The tesamorelin effects persisted after controlling for baseline VAT or SAT HU and area, and VAT [+2.3 HU, 95% confidence interval (4.5-7.3), P = 0.001) or SAT (+3.5 HU, 95% confidence interval (2.3-4.7), P < 0.001] area change. CONCLUSION: In PWH with central adiposity who experienced VAT quantity reductions on tesamorelin, VAT and SAT density increased independent of changes in fat quantity, suggesting that tesamorelin also improves VAT and SAT quality in this group.
Authors: Jordan E Lake; Carlee Moser; Liz Johnston; Clara Magyar; Scott D Nelson; Kristine M Erlandson; Todd T Brown; Grace A McComsey Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 5.958
Authors: Kathryn A Britton; Joseph M Massaro; Joanne M Murabito; Bernard E Kreger; Udo Hoffmann; Caroline S Fox Journal: J Am Coll Cardiol Date: 2013-07-10 Impact factor: 24.094
Authors: P Maurovich-Horvat; J Massaro; C S Fox; F Moselewski; C J O'Donnell; U Hoffmann Journal: Int J Obes (Lond) Date: 2006-09-05 Impact factor: 5.095
Authors: K Hotta; T Funahashi; Y Arita; M Takahashi; M Matsuda; Y Okamoto; H Iwahashi; H Kuriyama; N Ouchi; K Maeda; M Nishida; S Kihara; N Sakai; T Nakajima; K Hasegawa; M Muraguchi; Y Ohmoto; T Nakamura; S Yamashita; T Hanafusa; Y Matsuzawa Journal: Arterioscler Thromb Vasc Biol Date: 2000-06 Impact factor: 8.311
Authors: Marta Giralt; Pere Domingo; Jordi P Guallar; M Luísa Rodriguez de la Concepción; Marta Alegre; Joan C Domingo; Francesc Villarroya Journal: Antivir Ther Date: 2006
Authors: Julian Falutz; Soraya Allas; Koenraad Blot; Diane Potvin; Donald Kotler; Michael Somero; Daniel Berger; Stephen Brown; Gary Richmond; Jeffrey Fessel; Ralph Turner; Steven Grinspoon Journal: N Engl J Med Date: 2007-12-06 Impact factor: 91.245
Authors: J E Lake; P Debroy; D Ng; K M Erlandson; L A Kingsley; F J Palella; M J Budoff; W S Post; T T Brown Journal: Eur J Endocrinol Date: 2019-10 Impact factor: 6.664
Authors: Jordan E Lake; Takara L Stanley; Caroline M Apovian; Shalendar Bhasin; Todd T Brown; Jaqueline Capeau; Judith S Currier; Michael P Dube; Julian Falutz; Steven K Grinspoon; Giovanni Guaraldi; Esteban Martinez; Grace A McComsey; Fred R Sattler; Kristine M Erlandson Journal: Clin Infect Dis Date: 2017-05-15 Impact factor: 9.079